These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 24336915)
1. Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. Schoenberger SD; Kim SJ; Shah R; Sheng J; Cherney E JAMA Ophthalmol; 2014 Jan; 132(1):32-7. PubMed ID: 24336915 [TBL] [Abstract][Full Text] [Related]
2. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. Schoenberger SD; Kim SJ; Sheng J; Calcutt MW JAMA Ophthalmol; 2014 Feb; 132(2):150-4. PubMed ID: 24264034 [TBL] [Abstract][Full Text] [Related]
3. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Schoenberger SD; Kim SJ; Sheng J; Rezaei KA; Lalezary M; Cherney E Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5906-11. PubMed ID: 22871833 [TBL] [Abstract][Full Text] [Related]
4. Elevated Activating Transcription Factor 4 and Glucose-Regulated 78 Kda Protein Levels Correlate with Inflammatory Cytokines in the Aqueous Humor and Vitreous of Proliferative Diabetic Retinopathy. Wang Y; Gao S; Zhu Y; Shen X Curr Eye Res; 2017 Aug; 42(8):1202-1208. PubMed ID: 28497987 [TBL] [Abstract][Full Text] [Related]
5. Intraocular tumour necrosis factor ligand related molecule 1 A links disease progression of proliferative diabetic retinopathy after primary vitrectomy. Wang T; Li J; Xie R; Wang J; Zhang W; Jiang F; Du M; Wang X; Huang B; Brant R; Zhang C; Yan H Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):966-976. PubMed ID: 32064668 [TBL] [Abstract][Full Text] [Related]
6. Association between aqueous humor and vitreous fluid levels of Th17 cell-related cytokines in patients with proliferative diabetic retinopathy. Takeuchi M; Sato T; Sakurai Y; Taguchi M; Harimoto K; Karasawa Y; Ito M PLoS One; 2017; 12(5):e0178230. PubMed ID: 28558009 [TBL] [Abstract][Full Text] [Related]
7. Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial. Kim SJ; Lo WR; Hubbard GB; Srivastava SK; Denny JP; Martin DF; Yan J; Bergstrom CS; Cribbs BE; Schwent BJ; Aaberg TM Arch Ophthalmol; 2008 Sep; 126(9):1203-8. PubMed ID: 18779478 [TBL] [Abstract][Full Text] [Related]
8. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Suzuki Y; Nakazawa M; Suzuki K; Yamazaki H; Miyagawa Y Jpn J Ophthalmol; 2011 May; 55(3):256-263. PubMed ID: 21538000 [TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E Acar U; Acar DE; Tanriverdi C; Acar M; Ozdemir O; Erikci A; Ornek F Ocul Immunol Inflamm; 2017 Jun; 25(3):323-327. PubMed ID: 26765265 [TBL] [Abstract][Full Text] [Related]
10. Correlation of Aqueous, Vitreous, and Plasma Cytokine Levels in Patients With Proliferative Diabetic Retinopathy. Wu F; Phone A; Lamy R; Ma D; Laotaweerungsawat S; Chen Y; Zhao T; Ma W; Zhang F; Psaras C; Stewart JM Invest Ophthalmol Vis Sci; 2020 Feb; 61(2):26. PubMed ID: 32084272 [TBL] [Abstract][Full Text] [Related]
11. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Heier JS; Awh CC; Busbee BG; Waterbury LD; Daniel P; Stoller GL; Cleary TS Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822 [TBL] [Abstract][Full Text] [Related]
12. Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema. Yoshida S; Kubo Y; Kobayashi Y; Zhou Y; Nakama T; Yamaguchi M; Tachibana T; Ishikawa K; Arita R; Nakao S; Sassa Y; Oshima Y; Kono T; Ishibashi T Br J Ophthalmol; 2015 Jul; 99(7):960-6. PubMed ID: 25631486 [TBL] [Abstract][Full Text] [Related]
13. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Funatsu H; Yamashita H; Noma H; Mimura T; Nakamura S; Sakata K; Hori S Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):3-8. PubMed ID: 15258777 [TBL] [Abstract][Full Text] [Related]
15. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Patel JI; Tombran-Tink J; Hykin PG; Gregor ZJ; Cree IA Exp Eye Res; 2006 May; 82(5):798-806. PubMed ID: 16324700 [TBL] [Abstract][Full Text] [Related]
16. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy. Suzuki Y; Suzuki K; Yokoi Y; Miyagawa Y; Metoki T; Nakazawa M Retina; 2014 Jan; 34(1):165-71. PubMed ID: 23851630 [TBL] [Abstract][Full Text] [Related]
17. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. Bucci FA; Waterbury LD Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702 [TBL] [Abstract][Full Text] [Related]
18. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Praidou A; Klangas I; Papakonstantinou E; Androudi S; Georgiadis N; Karakiulakis G; Dimitrakos S Curr Eye Res; 2009 Feb; 34(2):152-61. PubMed ID: 19219687 [TBL] [Abstract][Full Text] [Related]
19. Intraocular activation of angiogenic and inflammatory pathways in uveal melanoma. Dunavoelgyi R; Funk M; Sacu S; Georgopoulos M; Zlabinger G; Zehetmayer M; Schmidt-Erfurth U Retina; 2012 Jul; 32(7):1373-84. PubMed ID: 22418780 [TBL] [Abstract][Full Text] [Related]
20. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy. Chernykh VV; Varvarinsky EV; Smirnov EV; Chernykh DV; Trunov AN Indian J Ophthalmol; 2015 Jan; 63(1):33-6. PubMed ID: 25686060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]